Date: 2011-03-22
Type of information: Grant
Company: Zealand Pharma (Denmark) Pepscan Therapeutics (The Netherlands)
Investors: European Eurostars Programme (EU)
Amount: €0.86 million
Funding type: grant
Planned used: The grant is awarded for the joint development of dual acting peptide drugs.
Others: Zealand Pharma and Pepscan have announced the joint award of an EU research and development grant of €860,000. The grant is awarded under the EUREKA Eurostars programme for the joint development of dual acting peptide drugs. The application by Zealand Pharma and Pepscan ranked no. 5 out of approximately 350 applications. With the collaboration, the two companies combine their competences to develop drugs to better treat chronic inflammations and gastrointestinal diseases, including Inflammatory Bowel Disease. The grant awarded to Zealand Pharma and Pepscan covers a two-year development period, which is expected to lead to the identification of a lead dual acting peptide drug candidate ready for preclinical development.
Therapeutic area: Inflammatory diseases
